STAG2 and neoplasm: In 110 primary tumor samples in which clinical outcomes data was available, there was a trend towards a modest decrease in overall survival in patients whose tumors had STAG2 loss (p = 0.10); this evaluation was limited, however, by small numbers of patients with STAG2 negative tumors in the analysis (Figure S10).